SCHEMBL3439154

SCHEMBL3439154

NC[C@H](O)COP=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5250595 1.00
SCHEMBL3439179 1.00
SCHEMBL7511925 1.00
SCHEMBL141573 0.77
SCHEMBL3418272 0.75
SCHEMBL4325538 0.75
SCHEMBL4320800 0.75
SCHEMBL12189698 0.75
SCHEMBL8860014 0.74
SCHEMBL29220459 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103228142-A GABA agonists for the treatment of diseases associated with metabolic syndrome and GABA combinations for the treatment or prevention of type I diabetes UNIV CALIFORNIA 2013-07-31 CN claimed
CN-107050456-B GABA agonists for the treatment of diseases associated with metabolic syndrome and GABA combinations for the treatment or prevention of type I diabetes 加利福尼亚大学董事会 2022-08-12 CN disclosed
CN-103228142-A GABA agonists for the treatment of diseases associated with metabolic syndrome and GABA combinations for the treatment or prevention of type I diabetes UNIV CALIFORNIA 2013-07-31 CN disclosed
US-7807658-B2 Use of GabaB receptor agonists ASTRAZENECA AB (SE) 2010-10-05 US disclosed
CN-101087614-A New use of GABAbeta receptor agonists ASTRAZENECA AB (SE) 2007-12-12 CN disclosed
US-20060160777-A1 New use of GABAbeta receptor agonists ASTRAZENECA AB (SE) 2006-07-20 US disclosed